Follicular Lymphoma

In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.

Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.

Based on data from the phase III AUGMENT trial, a supplemental new drug application for the&nbsp;R²&nbsp;regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA&nbsp;as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.

Results of a multi-institutional, retrospective analysis showed that radiotherapy in localized follicular lymphoma resulted in 68.9% of patients having no disease progression at 5 years with fewer than 2% of patients experiencing an in-field relapse, according to a study published in <em>Blood</em>.

A new retrospective analysis of 640 newly diagnosed patients with follicular lymphoma found that patients who had achieved partial remission after 4 or more cycles of bendamustine plus rituximab experienced improved duration of response on maintenance rituximab compared with patients who received no maintenance treatment or who were in complete remission following induction with bendamustine plus rituximab.

According to an exploratory analysis of the GALLIUM trial, obinutuzumab-based chemotherapy resulted in fewer incidences of disease progression compared to rituximab-based chemotherapy in previously untreated patients with advanced follicular lymphoma.

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.

John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma

A new pooled analysis concluded that the leading cause of death in patients with follicular lymphoma continues to be lymphoma, despite the widespread improvements in overall survival demonstrated with rituximab.

Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R² regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br /> &nbsp;

Jonathon B. Cohen, MD, MS, recently discussed treatment considerations and decisions in the case of a patient with follicular lymphoma.&nbsp;Cohen discussed the case scenario during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

The combination of ibrutinib and durvalumab demonstrated a modest clinical benefit for patients with relapsed or refractory follicular lymphoma and germinal center B-cell diffuse large B-cell lymphoma, according to the results of a phase I/II trial.

Viola Poeschel, MD,&nbsp;discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br /> &nbsp;

According to findings from the&nbsp;phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with&nbsp;relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.

In findings reported during the 2018 ASH Annual Meeting,&nbsp;brentuximab vedotin with conventional chemotherapy significantly improved&nbsp;progression-free survival compared with standard therapy for nonpediatric patients&nbsp;with stage III/IV Hodgkin lymphoma.

According to findings from the phase III ECHELON-2 trial presented at the 2018 ASH Annual Meeting, the use of brentuximab vedotin (Adcetris) in combination with chemotherapy demonstrated a clinically meaningful improvement in progression-free survival and overall survival in patients with CD30-expressing peripheral T-cell lymphoma. These data were also published online in&nbsp;<em>Lancet Oncology</em>.

Lenalidomide in addition to rituximab, called the R² regimen, led to a significant increase in progression-free survival compared with rituximab alone in patients with&nbsp;relapsed/refractory indolent non-Hodgkin lymphoma in results from the phase III AUGMENT trial.